EUVIMEDEUVIMED entdecken
Crossref

Crystallization Behavior of Amorphous Solid DispersionsRole of Nucleation and Nucleation Density

Bhushan Munjal iD, Snehal Shukla, Aifang Li, Alpana Thorat, Debbie Wanapun, Aaron Baldwin iD, Kapildev K Arora iD, Raj Suryanarayanan iD

Molecular Pharmaceutics · 02.11.2026 · 23 (11) · 5562-5571

DOI: 10.1021/acs.molpharmaceut.6c00648 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 06.10.2026. Verfasst von Bhushan Munjal und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota55455, United States. Hauptthemen laut MEDLINE: Flurbiprofen, Povidone. Die Arbeit nennt 35 Literaturangaben. Gefördert von: William and Mildred Peters Endowment fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The Tnose for nucleation (i.e., the temperature of the maximum nucleation rate without any crystal growth) of flurbiprofen-polyvinylpyrrolidone amorphous solid dispersions (ASDs) was determined using the time−temperature−transformation (TTT) diagram. Varying levels of nucleation were induced in ASDs by annealing for different time periods at Tnose for nucleation. Synchrotron X-ray diffractometry was utilized for real-time monitoring of the crystallization behavior upon wetting the ASDs with water. An increase in the nucleation density shortened the lag time and also accelerated drug crystallization. Williamson−Hall analysis of the X-ray data revealed a progressive reduction in the lattice strain (increased lattice order) of the crystallizing phase with increasing contact time with water. From performance perspectives, actualizing the solubility advantage of the amorphous drug necessitates retaining supersaturation for a sufficiently long period to allow absorption from the gastrointestinal tract. However, the presence of nuclei, by facilitating crystallization, can negate the solubility and the consequent bioavailability advantage of ASDs. A systematic framework for evaluating the “health” of ASDs was established, highlighting that the absence of nuclei would be an essential attribute of robust ASDs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FlurbiprofenPovidoneCrystallizationSolubilityX-Ray DiffractionBulk DrugsTemperatureChemistry, PharmaceuticalWater

Stichwörter der Autor:innen

TTTamorphous solid dispersionflurbiprofenlattice ordernucleationsynchrotron XRD

Substanzen

FlurbiprofenPovidoneBulk DrugsWater

Autor:innen und Institutionen

  • Department of Pharmaceutics, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota55455, United States.
  • Pfizer Worldwide Research and Development, Pharmaceutical Sciences Small Molecule (PSSM), Groton, Connecticut06340, United States.

ORCID-Profile: Bhushan Munjal, Aaron Baldwin, Kapildev K Arora, Raj Suryanarayanan

Förderung

  • William and Mildred Peters Endowment fund

Zitieren

APA

Munjal, B., Shukla, S., Li, A., Thorat, A., Wanapun, D., Baldwin, A., Arora, K. K., & Suryanarayanan, R. (2026). Crystallization Behavior of Amorphous Solid DispersionsRole of Nucleation and Nucleation Density. Molecular Pharmaceutics, 23(11), 5562-5571. https://doi.org/10.1021/acs.molpharmaceut.6c00648

Vancouver

Munjal B, Shukla S, Li A, Thorat A, Wanapun D, Baldwin A, et al. Crystallization Behavior of Amorphous Solid DispersionsRole of Nucleation and Nucleation Density. Molecular Pharmaceutics. 2026;23(11):5562-5571. doi:10.1021/acs.molpharmaceut.6c00648

BibTeX
@article{Munjal2026,
  author = {Munjal, Bhushan and Shukla, Snehal and Li, Aifang and Thorat, Alpana and Wanapun, Debbie and Baldwin, Aaron and Arora, Kapildev K and Suryanarayanan, Raj},
  title = {Crystallization Behavior of Amorphous Solid DispersionsRole of Nucleation and Nucleation Density},
  journal = {Molecular Pharmaceutics},
  year = {2026},
  volume = {23},
  number = {11},
  pages = {5562--5571},
  doi = {10.1021/acs.molpharmaceut.6c00648}
}
Kostenlos starten →